Poul Jennum1, Rikke Ibsen, Stine Knudsen, Jakob Kjellberg. 1. Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Center for Healthy Aging, Faculty of Health Sciences, University of Copenhagen, Glostrup Hospital, Copenhagen, Denmark. POJE@glo.regionh.dk
Abstract
STUDY OBJECTIVES: To identify the factual morbidity and mortality of narcolepsy in a controlled design. SETTING: National Patient Registry. PATIENTS: All national diagnosed patients (757) with health information at least 3 years prior to and after diagnose of narcolepsy. CONTROLS: Randomly selected four citizens (3,013) matched for age, sex, and socioeconomic status from the Danish Civil Registration System Statistics. RESULTS: Increased morbidity prior to narcolepsy diagnosis included (odds ratio, 95% confidence interval):- diseases of the endocrine, nutritional, and metabolic systems (2.10, 1.32-3.33); nervous system (5.27, 3.65-7.60); musculoskeletal system (1.59, 1.23-2.05); and other abnormal symptoms and laboratory findings (1.66, 1.25-2.22). After the diagnosis, narcolepsy patients experienced diseases of the endocrine, nutritional, and metabolic (2.31, 1.51-3.54), nervous (9.19, 6.80-12.41), musculoskeletal (1.70, 1.28-2.26), eye (1.67, 1.03-2.71), and respiratory systems (1.84, 1.21-2.81). Specific diagnoses were diabetes (2.4, 1,2-4.7, P < 0.01), obesity (13.4, 3.1-57.6, P < 0.001), sleep apnea (19.2, 7.7-48.3, P < 0.001), other sleep disorders (78.5, 11.8-523.3, P < 0.001), chronic obstructive pulmonary disease (2.8, 1.4-5.8, P < 0.01), lower back pain (2.5, 1.4-4.2, P < 0.001), arthrosis/arthritis (2.5, 1.3-4.8, P < 0.01), observation of neurological diseases (3.5, 1.9-6.5, P < 0.001), observation of other diseases (1.7, 1.2-2.5, P < 0.01), and rehabilitation (5.0, 1.5-16.5, P < 0.005). There was a trend towards greater mortality in narcolepsy (P = 0.07). CONCLUSIONS: Patients with narcolepsy present higher morbidity several years prior to diagnose and even higher thereafter. The mortality rate due to narcolepsy was slightly but not significantly higher.
STUDY OBJECTIVES: To identify the factual morbidity and mortality of narcolepsy in a controlled design. SETTING: National Patient Registry. PATIENTS: All national diagnosed patients (757) with health information at least 3 years prior to and after diagnose of narcolepsy. CONTROLS: Randomly selected four citizens (3,013) matched for age, sex, and socioeconomic status from the Danish Civil Registration System Statistics. RESULTS: Increased morbidity prior to narcolepsy diagnosis included (odds ratio, 95% confidence interval):- diseases of the endocrine, nutritional, and metabolic systems (2.10, 1.32-3.33); nervous system (5.27, 3.65-7.60); musculoskeletal system (1.59, 1.23-2.05); and other abnormal symptoms and laboratory findings (1.66, 1.25-2.22). After the diagnosis, narcolepsypatients experienced diseases of the endocrine, nutritional, and metabolic (2.31, 1.51-3.54), nervous (9.19, 6.80-12.41), musculoskeletal (1.70, 1.28-2.26), eye (1.67, 1.03-2.71), and respiratory systems (1.84, 1.21-2.81). Specific diagnoses were diabetes (2.4, 1,2-4.7, P < 0.01), obesity (13.4, 3.1-57.6, P < 0.001), sleep apnea (19.2, 7.7-48.3, P < 0.001), other sleep disorders (78.5, 11.8-523.3, P < 0.001), chronic obstructive pulmonary disease (2.8, 1.4-5.8, P < 0.01), lower back pain (2.5, 1.4-4.2, P < 0.001), arthrosis/arthritis (2.5, 1.3-4.8, P < 0.01), observation of neurological diseases (3.5, 1.9-6.5, P < 0.001), observation of other diseases (1.7, 1.2-2.5, P < 0.01), and rehabilitation (5.0, 1.5-16.5, P < 0.005). There was a trend towards greater mortality in narcolepsy (P = 0.07). CONCLUSIONS:Patients with narcolepsy present higher morbidity several years prior to diagnose and even higher thereafter. The mortality rate due to narcolepsy was slightly but not significantly higher.
Authors: C Peyron; J Faraco; W Rogers; B Ripley; S Overeem; Y Charnay; S Nevsimalova; M Aldrich; D Reynolds; R Albin; R Li; M Hungs; M Pedrazzoli; M Padigaru; M Kucherlapati; J Fan; R Maki; G J Lammers; C Bouras; R Kucherlapati; S Nishino; E Mignot Journal: Nat Med Date: 2000-09 Impact factor: 53.440
Authors: Simon W Kok; Sebastiaan Overeem; Tommy L S Visscher; Gert Jan Lammers; Jaap C Seidell; Hanno Pijl; Arend E Meinders Journal: Obes Res Date: 2003-09
Authors: Valentina A Andreeva; Marion J Torres; Damien Léger; Virginie Bayon; Paloma Gonzalez; Fabien Szabo de Edelenyi; Serge Hercberg; Pilar Galan Journal: Int J Behav Med Date: 2017-08